Indicator type	Main activity, secondary activity or tool required for...	Total
Companies carrying out R&D in Biotechnology	Total	1,602
Companies carrying out R&D in Biotechnology	Main	773
Companies carrying out R&D in Biotechnology	Secondary	279
Companies carrying out R&D in Biotechnology	Tool required	550
% Companies by type of biotechnology used: Genetic Code	Total	28.8
% Companies by type of biotechnology used: Genetic Code	Main	35.7
% Companies by type of biotechnology used: Genetic Code	Secondary	27.0
% Companies by type of biotechnology used: Genetic Code	Tool required	20.0
% Companies by type of biotechnology used: Functional Units	Total	38.9
% Companies by type of biotechnology used: Functional Units	Main	45.8
% Companies by type of biotechnology used: Functional Units	Secondary	37.8
% Companies by type of biotechnology used: Functional Units	Tool required	29.8
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Total	21.5
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Main	25.9
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Secondary	19.7
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering	Tool required	16.2
% Companies by type of biotechnology used: Bioprocesses	Total	49.5
% Companies by type of biotechnology used: Bioprocesses	Main	40.1
% Companies by type of biotechnology used: Bioprocesses	Secondary	56.6
% Companies by type of biotechnology used: Bioprocesses	Tool required	59.2
% Companies by type of biotechnology used: Subcellular Organisms	Total	8.7
% Companies by type of biotechnology used: Subcellular Organisms	Main	11.1
% Companies by type of biotechnology used: Subcellular Organisms	Secondary	6.4
% Companies by type of biotechnology used: Subcellular Organisms	Tool required	6.5
% Companies by type of biotechnology used: Bioinformatics	Total	26.9
% Companies by type of biotechnology used: Bioinformatics	Main	34.9
% Companies by type of biotechnology used: Bioinformatics	Secondary	23.5
% Companies by type of biotechnology used: Bioinformatics	Tool required	17.2
% Companies by type of biotechnology used: Nanobiotechnology	Total	11.8
% Companies by type of biotechnology used: Nanobiotechnology	Main	16.8
% Companies by type of biotechnology used: Nanobiotechnology	Secondary	9.7
% Companies by type of biotechnology used: Nanobiotechnology	Tool required	5.9
% Companies by type of biotechnology used: Other	Total	18.0
% Companies by type of biotechnology used: Other	Main	17.4
% Companies by type of biotechnology used: Other	Secondary	18.4
% Companies by type of biotechnology used: Other	Tool required	18.6
% Companies by final application areas of biotechnology use: Human Health	Total	48.4
% Companies by final application areas of biotechnology use: Human Health	Main	66.4
% Companies by final application areas of biotechnology use: Human Health	Secondary	37.1
% Companies by final application areas of biotechnology use: Human Health	Tool required	28.7
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Total	19.1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Main	20.9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Secondary	18.8
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture	Tool required	16.8
% Companies by final application areas of biotechnology use: Food Products	Total	28.9
% Companies by final application areas of biotechnology use: Food Products	Main	20.2
% Companies by final application areas of biotechnology use: Food Products	Secondary	32.9
% Companies by final application areas of biotechnology use: Food Products	Tool required	39.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Total	24.8
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Main	19.1
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Secondary	30.4
% Companies by final application areas of biotechnology use: Agriculture and Forestry	Tool required	30.1
% Companies by final application areas of biotechnology use: Environment	Total	18.2
% Companies by final application areas of biotechnology use: Environment	Main	14.8
% Companies by final application areas of biotechnology use: Environment	Secondary	29.5
% Companies by final application areas of biotechnology use: Environment	Tool required	17.3
% Companies by final application areas of biotechnology use: Industry	Total	13.5
% Companies by final application areas of biotechnology use: Industry	Main	12.7
% Companies by final application areas of biotechnology use: Industry	Secondary	17.1
% Companies by final application areas of biotechnology use: Industry	Tool required	12.7
R&D personnel in Biotechnology (PP)	Total	19,307
R&D personnel in Biotechnology (PP)	Main	9,595
R&D personnel in Biotechnology (PP)	Secondary	3,420
R&D personnel in Biotechnology (PP)	Tool required	6,293
R&D personnel in Biotechnology (PP): Research personnel	Total	10,779
R&D personnel in Biotechnology (PP): Research personnel	Main	5,672
R&D personnel in Biotechnology (PP): Research personnel	Secondary	1,945
R&D personnel in Biotechnology (PP): Research personnel	Tool required	3,162
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Total	8,528
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Main	3,923
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Secondary	1,474
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel	Tool required	3,130
R&D personnel in Biotechnology (PP). Women	Total	11,155
R&D personnel in Biotechnology (PP). Women	Main	5,882
R&D personnel in Biotechnology (PP). Women	Secondary	1,909
R&D personnel in Biotechnology (PP). Women	Tool required	3,364
R&D personnel in Biotechnology (PP). Women: Research personnel	Total	5,934
R&D personnel in Biotechnology (PP). Women: Research personnel	Main	3,223
R&D personnel in Biotechnology (PP). Women: Research personnel	Secondary	1,036
R&D personnel in Biotechnology (PP). Women: Research personnel	Tool required	1,675
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Total	5,222
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Main	2,660
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Secondary	873
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel	Tool required	1,689
R&D personnel in Biotechnology (FTE)	Total	14,093.7
R&D personnel in Biotechnology (FTE)	Main	7,496.3
R&D personnel in Biotechnology (FTE)	Secondary	2,228.2
R&D personnel in Biotechnology (FTE)	Tool required	4,369.2
R&D personnel in Biotechnology (FTE): Research personnel	Total	8,073.8
R&D personnel in Biotechnology (FTE): Research personnel	Main	4,470.2
R&D personnel in Biotechnology (FTE): Research personnel	Secondary	1,271.2
R&D personnel in Biotechnology (FTE): Research personnel	Tool required	2,332.4
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Total	6,019.9
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Main	3,026.1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Secondary	957.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel	Tool required	2,036.8
R&D personnel in Biotechnology (FTE). Women	Total	8,305.8
R&D personnel in Biotechnology (FTE). Women	Main	4,623.1
R&D personnel in Biotechnology (FTE). Women	Secondary	1,273.3
R&D personnel in Biotechnology (FTE). Women	Tool required	2,409.5
R&D personnel in Biotechnology (FTE). Women: Research personnel	Total	4,482.6
R&D personnel in Biotechnology (FTE). Women: Research personnel	Main	2,545.4
R&D personnel in Biotechnology (FTE). Women: Research personnel	Secondary	684.2
R&D personnel in Biotechnology (FTE). Women: Research personnel	Tool required	1,253.0
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Total	3,823.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Main	2,077.7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Secondary	589.1
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel	Tool required	1,156.5
Expenditure on internal R&D in Biotechnology (thousands of euros)	Total	1,462,695
Expenditure on internal R&D in Biotechnology (thousands of euros)	Main	791,776
Expenditure on internal R&D in Biotechnology (thousands of euros)	Secondary	281,859
Expenditure on internal R&D in Biotechnology (thousands of euros)	Tool required	389,060
1) By type of expenditure: Current expenditure	Total	1,347,574
1) By type of expenditure: Current expenditure	Main	722,397
1) By type of expenditure: Current expenditure	Secondary	267,005
1) By type of expenditure: Current expenditure	Tool required	358,172
1.1) Labour expenditure of research personnel	Total	470,714
1.1) Labour expenditure of research personnel	Main	258,146
1.1) Labour expenditure of research personnel	Secondary	87,519
1.1) Labour expenditure of research personnel	Tool required	125,049
1.2) Labour expenditure of technical and auxiliary personnel	Total	258,791
1.2) Labour expenditure of technical and auxiliary personnel	Main	128,142
1.2) Labour expenditure of technical and auxiliary personnel	Secondary	39,887
1.2) Labour expenditure of technical and auxiliary personnel	Tool required	90,762
1.3) Other current expenditure	Total	618,069
1.3) Other current expenditure	Main	336,109
1.3) Other current expenditure	Secondary	139,599
1.3) Other current expenditure	Tool required	142,361
2) By type of expenditure: Capital expenditure	Total	115,121
2) By type of expenditure: Capital expenditure	Main	69,379
2) By type of expenditure: Capital expenditure	Secondary	14,854
2) By type of expenditure: Capital expenditure	Tool required	30,888
2.1) Land and buildings	Total	21,877
2.1) Land and buildings	Main	12,452
2.1) Land and buildings	Secondary	1,281
2.1) Land and buildings	Tool required	8,144
2.2) Equipment and tools	Total	54,592
2.2) Equipment and tools	Main	26,091
2.2) Equipment and tools	Secondary	10,937
2.2) Equipment and tools	Tool required	17,563
2.3) Acquisition of specific R&D software	Total	4,673
2.3) Acquisition of specific R&D software	Main	2,604
2.3) Acquisition of specific R&D software	Secondary	803
2.3) Acquisition of specific R&D software	Tool required	1,266
2.4) Other R&D-specific IP products	Total	33,978
2.4) Other R&D-specific IP products	Main	28,231
2.4) Other R&D-specific IP products	Secondary	1,833
2.4) Other R&D-specific IP products	Tool required	3,914
1.1) By origin of funds: Own funds	Total	1,013,505
1.1) By origin of funds: Own funds	Main	506,869
1.1) By origin of funds: Own funds	Secondary	212,196
1.1) By origin of funds: Own funds	Tool required	294,440
1.2) By origin of funds: Funds from the Business sector	Total	206,072
1.2) By origin of funds: Funds from the Business sector	Main	133,006
1.2) By origin of funds: Funds from the Business sector	Secondary	31,303
1.2) By origin of funds: Funds from the Business sector	Tool required	41,763
1.3) By origin of funds: Funds from the Public Administration sector	Total	158,706
1.3) By origin of funds: Funds from the Public Administration sector	Main	94,278
1.3) By origin of funds: Funds from the Public Administration sector	Secondary	28,526
1.3) By origin of funds: Funds from the Public Administration sector	Tool required	35,902
1.4) By origin of funds: Funds from the Higher Education sector	Total	615
1.4) By origin of funds: Funds from the Higher Education sector	Main	514
1.4) By origin of funds: Funds from the Higher Education sector	Secondary	0
1.4) By origin of funds: Funds from the Higher Education sector	Tool required	101
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Total	9,828
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Main	8,757
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Secondary	38
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector	Tool required	1,033
1.6) By origin of funds: Funds from the rest of the world	Total	73,969
1.6) By origin of funds: Funds from the rest of the world	Main	48,351
1.6) By origin of funds: Funds from the rest of the world	Secondary	9,796
1.6) By origin of funds: Funds from the rest of the world	Tool required	15,821
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Total	96,238
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Main	75,967
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Secondary	12,035
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros)	Tool required	8,236
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Total	65,364
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Main	50,684
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Secondary	7,546
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain	Tool required	7,134
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Total	30,874
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Main	25,283
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Secondary	4,489
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world	Tool required	1,102
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Total	46.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Main	54.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Secondary	43.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital	Tool required	35.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Total	17.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Main	14.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Secondary	19.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information	Tool required	18.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Total	25.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Main	25.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Secondary	24.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources	Tool required	26.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Total	13.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Main	12.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Secondary	14.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain	Tool required	14.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Total	18.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Main	21.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Secondary	18.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets	Tool required	14.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Total	17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Main	20.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Secondary	15.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels	Tool required	13.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Total	20.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Main	21.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Secondary	18.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception	Tool required	19.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Total	47.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Main	54.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Secondary	43.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements	Tool required	38.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Total	53.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Main	59.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Secondary	51.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost	Tool required	46.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Total	21.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Main	20.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Secondary	27.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting	Tool required	20.6
% Companies with international revenues related to biotechnology activities	Total	22.2
% Companies with international revenues related to biotechnology activities	Main	29.6
% Companies with international revenues related to biotechnology activities	Secondary	16.8
% Companies with international revenues related to biotechnology activities	Tool required	14.5
% Companies representing international revenues related to biotechnology activities	Total	2.2
% Companies representing international revenues related to biotechnology activities	Main	16.8
% Companies representing international revenues related to biotechnology activities	Secondary	0.6
% Companies representing international revenues related to biotechnology activities	Tool required	1.6
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Total	55.2
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Main	66.4
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Secondary	34.1
% International revenues related to biotechnology activities distributed in: Revenues from the EU	Tool required	43.4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Total	44.8
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Main	33.6
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Secondary	65.9
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world	Tool required	56.6
% International revenues related to biotechnology activities by classification: International trade in goods and services	Total	87.2
% International revenues related to biotechnology activities by classification: International trade in goods and services	Main	80.7
% International revenues related to biotechnology activities by classification: International trade in goods and services	Secondary	97.2
% International revenues related to biotechnology activities by classification: International trade in goods and services	Tool required	95.0
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total	4.6
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Main	7.1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Secondary	0.3
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Tool required	1.8
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Total	4.3
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Main	6.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Secondary	2.6
% International revenues related to biotechnology activities by classification: Subsidies from external sources	Tool required	0.7
% International revenues related to biotechnology activities by classification: Other	Total	3.9
% International revenues related to biotechnology activities by classification: Other	Main	5.6
% International revenues related to biotechnology activities by classification: Other	Secondary	0.0
% International revenues related to biotechnology activities by classification: Other	Tool required	2.4